Mr. Michael Frank reports

REVIVE THERAPEUTICS PROVIDES UPDATE ON RESEARCH STUDY EVALUATING BUCILLAMINE FOR NERVE AGENT EXPOSURE

Revive Therapeutics Ltd. has provided an update on the research study evaluating bucillamine as a potential treatment for nerve agent exposure. This study is conducted in partnership with Defence R&D Canada -- Suffield Research Centre, an agency of the Canadian Department of National Defence, which brings a wealth of expertise and resources to the project. The DRDC is investigating pharmacological compounds, including bucillamine, that can mitigate nerve agent induced brain injury.

After recent discussions with the DRDC, the research study on bucillamine is set to conclude by June, 2025, focusing on GABA receptor antibodies and data confirmation for effect size. Positive outcomes may accelerate human clinical trials in the second half of 2025, aiming for Food and Drug Administration and Health Canada approvals for treating nerve agent or organophosphate pesticide poisoning. Additionally, bucillamine's potential in traumatic brain injury from concussive/explosive forces and viral infections is under exploration.

Nerve agents are chemicals that affect the nervous system. Nerve agents are highly toxic regardless of the route of exposure. The main chemical nerve agents that are man-made and manufactured for use in chemical warfare are sarin, soman, tabun and VX. These nerve agents are known to be present in military stockpiles. Exposure to nerve agents can occur due to chemical warfare or accidental release from a military storage facility. Exposure to nerve agents can cause tightness of the chest, excessive salivation, abdominal cramps, diarrhea, blurred vision, tremors and death.

Recent studies have shown that anti-oxidant compounds such as n-acetylcysteine could be beneficial in limiting seizure activity and improving the anti-convulsant efficacy of GABA-mediating drugs such as diazepam.

Bucillamine is a significantly more effective anti-oxidant than NAC and has the potential to provide increased efficacy against seizure activity while limiting the anticoagulant and bleeding event liability observed with NAC. The overall objective of the research project is to investigate pharmacological means for neuroprotection of GABA(A) receptors, which are required for the effectiveness of currently fielded anticonvulsant therapies. Bucillamine and NAC will be evaluated to determine the effect on GABA(A) receptor endocytosis and the effect on diazepam effectiveness in terminating seizures. Any additional anti-oxidant effects on seizure activity and survival will also be assessed.

About Revive Therapeutics Ltd.

Revive Therapeutics is a life science company focused on the research and development of therapeutics for infectious diseases and medical countermeasures. Revive prioritizes its drug development efforts to take advantage of several regulatory incentives awarded by the FDA, such as emergency use authorization, orphan drug, fast track and breakthrough therapy designations. Currently, the company is exploring the use of bucillamine for the potential treatment of nerve agent exposure and long COVID. Revive is also advancing the development of psilocybin and molecular hydrogen therapeutics through various programs.

We seek Safe Harbor.